<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VALPROIC ACID (DIVALPROEX SODIUM, SODIUM VALPROATE) <img border="0" src="../images/pr.gif"/></span><br/>(val-proe'ic)<br/><span class="topboxtradename">Depacon, </span><span class="topboxtradename">Depakene, </span><span class="topboxtradename">Depakote, </span><span class="topboxtradename">Depakote ER, </span><span class="topboxtradename">Depakote Sprinkle, </span><span class="topboxtradename">Epival <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Zalkote<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">anticonvulsant</span>; <span class="classification">gaba inhibitor</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules; 125 mg sprinkle capsules; 125 mg, 250 mg, 500 mg delayed-release tablets; 500 mg sustained-release tablets; 250 mg/5 mL syrup; 100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Anticonvulsant unrelated chemically to other drugs used to treat seizure disorders. Mechanism of action unknown; may be related
         to increased bioavailability of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to brain neurons. Inhibits
         secondary phase of platelet aggregation.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Depresses abnormal neuron discharges in the CNS, thus decreasing seizure activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Alone or with other anticonvulsants in management of absence (petit mal) and mixed seizures; mania; migraine headache prophylaxis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Status epilepticus refractory to IV diazepam, petit mal variant seizures, febrile seizures in children, other types of seizures
         including psychomotor (temporal lobe), myoclonic, akinetic and tonic-clonic seizures, photosensitivity seizures, and those
         refractory to other anticonvulsants.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to valproate sodium; thrombocytopenia, patient with bleeding disorders or liver dysfunction or disease; cirrhosis,
         pancreatitis; congenital metabolic disorders, those with severe seizures, or on multiple anticonvulsant drugs; AIDS; pregnancy
         (category D), lactation; child 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of kidney disease, renal impairment or failure; adjunctive treatment with other anticonvulsants; congenital metabolic
         disorders, those with severe epilepsy, use as sole anticonvulsant drug; hypoalbuminemia; organic brain syndrome; children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td>
<p> 				Note: May need to increase dose when converting from immediate release to extended-release products 			</p><span class="indicationtitle">Management of Seizures, Mania</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 15 mg/kg/d in divided doses when total daily dose &gt;250 mg, increase at 1 wk intervals by 510 mg/kg/d until seizures
               are controlled or adverse effects develop (max: 60 mg/kg/d)<br/><br/><span class="indicationtitle">Migraine Headache Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg b.i.d. (max: 1000 mg/d) or <span class="rdroute">Depakote ER</span> 500 mg q.d. <small>x</small> 1 wk, may increase to 1000 mg q.d.<br/><br/><span class="indicationtitle">Mania</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg t.i.d. (max: 60 mg/kg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give tablets and capsules whole; instruct patient to swallow whole &amp; not to chew. Instruct to swallow sprinkle capsules whole
            or sprinkle entire contents on teaspoonful of soft food, and instruct to not chew food.
         </li>
<li>Avoid using a carbonated drink as diluent for the syrup because it will release drug from delivery vehicle; free drug painfully
            irritates oral and pharyngeal membranes.
         </li>
<li>Reduce gastric irritation by administering drug with food because serious GI adverse effects can lead to discontinuation of
            therapy. Enteric-coated tablet or syrup formulation is usually well tolerated.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute each dose in 50 mL or more of D5W, NS, or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give a single dose over at least 60 min (<img src="../images/special/lesserorequal.gif"/>20 mg/min). Avoid rapid infusion.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> No compatibility data available. Should avoid mixing with other drugs. 
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Breakthrough seizures, <span class="speceff-common">sedation, drowsiness,</span> dizziness, increased alertness, hallucinations, emotional upset, aggression; <span class="speceff-life">deep coma, death (with overdose)</span>. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, indigestion (transient),</span> hypersalivation, anorexia with weight loss, increased appetite with weight gain, abdominal cramps, diarrhea, constipation,
      <span class="speceff-life">liver failure, pancreatitis</span>. <span class="typehead">Hematologic:</span> <span class="speceff-common">Prolonged bleeding time,</span> leukopenia, lymphocytosis, thrombocytopenia, hypofibrinogenemia, <span class="speceff-life">bone marrow depression</span>, anemia. <span class="typehead">Skin:</span> Skin rash, photosensitivity, transient hair loss, curliness or waviness of hair. <span class="typehead">Endocrine:</span> Irregular menses, secondary amenorrhea. <span class="typehead">Metabolic:</span> Hyperammonemia (usually asymptomatic) hyperammonemic encephalopathy in patients with urea cycle disorders. <span class="typehead">Respiratory:</span> Pulmonary edema (with overdose). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Valproic acid produces false-positive results for <span class="alt">urine ketones,</span> elevated <span class="alt">AST,</span> <span class="alt">ALT,</span> <span class="alt">LDH,</span> and <span class="alt">serum alkaline phosphatase,</span> prolonged <span class="alt">bleeding time,</span> altered <span class="alt">thyroid function tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> and other <span class="classification">cns depressants</span> potentiate depressant effects; other <span class="classification">anticonvulsants</span>, <span class="classification">barbiturates</span> increase or decrease anticonvulsant and <span class="classification">barbiturate</span> levels; <b>haloperidol,</b> <b>loxapine,</b> <b>maprotiline,</b> <span class="classification">maoi</span>s, <span class="classification">phenothiazines</span>, <span class="classification">thioxanthenes</span>, <span class="classification">tricyclic antidepressants</span> can increase CNS depression or lower seizure threshold; <b>aspirin,</b> <b>dipyridamole,</b> <b>warfarin</b> increase risk of spontaneous bleeding and decrease clotting; <b>clonazepam</b> may precipitate absence seizures; <span class="classification">salicylates</span>, <b>cimetidine</b> may increase valproic acid levels and toxicity. <b>Mefloquine</b> can decrease valproic acid levels; <b>isoniazid</b> may increase valproic acid levels and hepatotoxicity; <b>meropenem</b> may decrease valproic acid levels; <b>cholestyramine</b> may decrease absorption. <span class="typehead">Herbal:</span> <b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 14 h valproic acid; 35 h divalproex. <span class="typehead">Therapeutic Range:</span> 50100 g/mL. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine; small amount excreted in feces and expired air. <span class="typehead">Half-Life:</span> 520 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness achieved with serum levels of valproic acid at 50100 mcg/mL.</li>
<li>Monitor patient alertness especially with multiple drug therapy for seizure control. Evaluate plasma levels of the adjunctive
            anticonvulsants periodically as indicators for possible neurologic toxicity.
         </li>
<li>Monitor patient carefully during dose adjustments and promptly report presence of adverse effects. Increased dosage is associated
            with frequency of adverse effects.
         </li>
<li>Lab tests: Perform baseline platelet counts, bleeding time, and serum ammonia, then repeat at least q2mo, especially during
            the first 6 mo of therapy.
         </li>
<li>Multiple drugs for seizure control increase the risk of hyperammonemia, marked by lethargy, anorexia, asterixis, increased
            seizure frequency, and vomiting. Report such symptoms promptly to physician. If they persist with decreased dosage, the drug
            will be discontinued.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not discontinue therapy abruptly; such action could result in loss of seizure control. Consult physician before you stop
            or alter dosage regimen.
         </li>
<li>Note to diabetic patients: Drug may cause a false-positive test for urine ketones. Notify physician if this occurs; a differential
            diagnostic blood test may be indicated.
         </li>
<li>Notify physician promptly if spontaneous bleeding or bruising occurs (e.g., petechiae, ecchymotic areas, otorrhagia, epistaxis,
            melena).
         </li>
<li>Withhold dose and notify physician for following symptoms: visual disturbances, rash, jaundice, light-colored stools, protracted
            vomiting, diarrhea. Fatal liver failure has occurred in patients receiving this drug.
         </li>
<li>Avoid alcohol and self-medication with other depressants during therapy.</li>
<li>Consult physician before using any OTC drugs during anticonvulsant therapy. Combination drugs containing aspirin, sedatives,
            and medications for hay fever or other allergies are particularly <small>UNSAFE</small>.
         </li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Inform doctor or dentist before any kind of surgery that you are taking valproic acid.</li>
<li>Carry medical identification card at all times. It needs to indicate medical diagnosis, medication(s), physician's name, address,
            and telephone number.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>